The longest reported sibling survivors of a severe form of congenital myasthenic syndrome with the ALG14 pathogenic variant

Author(s):  
Yu Katata ◽  
Saki Uneoka ◽  
Naoya Saijyo ◽  
Yu Aihara ◽  
Takamitsu Miyazoe ◽  
...  
2008 ◽  
Vol 46 (3) ◽  
pp. 203-208 ◽  
Author(s):  
R A Maselli ◽  
J J Ng ◽  
J A Anderson ◽  
O Cagney ◽  
J Arredondo ◽  
...  

2021 ◽  
pp. 1-3
Author(s):  
Setareh Alabaf ◽  
Karen O'Connell ◽  
Sithara Ramdas ◽  
David Beeson ◽  
Jacqueline Palace

Congenital Myasthenic Syndrome (CMS) are a rare group of genetic disorders of neuromuscular transmission. Some subtypes of CMS can be associated with respiratory and bulbar weakness and these patients may therefore be at high risk of developing a severe disease from COVID-19. We screened 73 patients with genetically confirmed CMS who were attending the UK national referral centre for evidence of previous Severe Acute Respiratory Syndrome Corona Virus 2 infection and their clinical outcome. Of 73 patients, seven had history of confirmed COVID-19. None of the infected patients developed a severe disease, and there were no signals that CMS alone carries a high risk of severe disease from COVID-19.


2021 ◽  
Author(s):  
Christina E. Hoei-Hansen ◽  
Marie L. B. Tygesen ◽  
Morten Dunø ◽  
John Vissing ◽  
Martin Ballegaard ◽  
...  

Abstract Aim The diagnostic workup in patients with delayed motor milestones suspected of having either myopathy or a congenital myasthenic syndrome is complex. Our hypothesis was that performance of a muscle biopsy and neurophysiology including stimulated single-fiber electromyography during an anesthetic procedure, combined with genetic testing has a high diagnostic quality. Materials and Methods Clinical and paraclinical data were retrospectively collected from 24 patients aged from 1 month to 10 years (median: 5.2 years). Results Neurophysiology examination was performed in all patients and was abnormal in 11 of 24. No patients had findings suggestive of a myasthenic syndrome. Muscle biopsy was performed in 21 of 24 and was normal in 16. Diagnostic findings included nemaline rods, inclusion bodies, fiber size variability, and type-II fiber atrophy. Genetic testing with either a gene panel or exome sequencing was performed in 18 of 24 patients, with pathogenic variants detected in ACTA1, NEB, SELENON, GRIN2B, SCN8A, and COMP genes. Conclusion Results supporting a neuromuscular abnormality were found in 15 of 24. In six patients (25%), we confirmed a genetic diagnosis and 12 had a clinical neuromuscular diagnosis. The study suggests that combined use of neurophysiology and muscle biopsy in cases where genetic testing does not provide a diagnosis can be useful in children with delayed motor milestones and clinical evidence of a neuromuscular disease.


2015 ◽  
Vol 97 (6) ◽  
pp. 878-885 ◽  
Author(s):  
Clare V. Logan ◽  
Judith Cossins ◽  
Pedro M. Rodríguez Cruz ◽  
David A. Parry ◽  
Susan Maxwell ◽  
...  

2012 ◽  
Vol 316 (1-2) ◽  
pp. 112-115 ◽  
Author(s):  
Esther Leshinsky-Silver ◽  
Daniel Shapira ◽  
Keren Yosovitz ◽  
Mira Ginsberg ◽  
Tally Lerman-Sagie ◽  
...  

2018 ◽  
Vol 265 (3) ◽  
pp. 708-713 ◽  
Author(s):  
Eduardo de Paula Estephan ◽  
Cláudia Ferreira da Rosa Sobreira ◽  
André Clériston José dos Santos ◽  
Pedro José Tomaselli ◽  
Wilson Marques ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document